These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 15878440)
1. Isolation of cholesterol-dependent Candida glabrata from clinical specimens. Hazen KC; Stei J; Darracott C; Breathnach A; May J; Howell SA Diagn Microbiol Infect Dis; 2005 May; 52(1):35-7. PubMed ID: 15878440 [TBL] [Abstract][Full Text] [Related]
2. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples]. Hüseyin A; Sancak B; Arikan S Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710 [TBL] [Abstract][Full Text] [Related]
3. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778 [TBL] [Abstract][Full Text] [Related]
4. Cholesterol dependent and Amphotericin B resistant isolates of a Candida glabrata strain from an Intensive Care Unit patient. Rezusta A; Aspiroz C; Boekhout T; Cano JF; Theelen B; Guarro J; Rubio MC Med Mycol; 2008 May; 46(3):265-8. PubMed ID: 18404554 [TBL] [Abstract][Full Text] [Related]
6. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan. Yang YL; Li SY; Cheng HH; Lo HJ; BMC Infect Dis; 2005 Nov; 5():99. PubMed ID: 16266438 [TBL] [Abstract][Full Text] [Related]
7. Azole resistance of Candida glabrata in a case of recurrent fungemia. Posteraro B; Tumbarello M; La Sorda M; Spanu T; Trecarichi EM; De Bernardis F; Scoppettuolo G; Sanguinetti M; Fadda G J Clin Microbiol; 2006 Aug; 44(8):3046-7. PubMed ID: 16891541 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance. Lee I; Zaoutis TE; Fishman NO; Morales KH; Nachamkin I; Lautenbach E Am J Infect Control; 2010 Aug; 38(6):456-60. PubMed ID: 20371135 [TBL] [Abstract][Full Text] [Related]
10. Candida glabrata fungemia: experience in a tertiary care center. Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662 [TBL] [Abstract][Full Text] [Related]
11. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ; Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of oral Candida to seven antifungal agents. Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594 [TBL] [Abstract][Full Text] [Related]
14. Genotyping of clinical isolates of Candida glabrata from Iran by multilocus sequence typing and determination of population structure and drug resistance profile. Amanloo S; Shams-Ghahfarokhi M; Ghahri M; Razzaghi-Abyaneh M Med Mycol; 2018 Feb; 56(2):207-215. PubMed ID: 28482076 [TBL] [Abstract][Full Text] [Related]
15. Relationship between respiration deficiency and azole resistance in clinical Candida glabrata. Peng Y; Dong D; Jiang C; Yu B; Wang X; Ji Y FEMS Yeast Res; 2012 Sep; 12(6):719-27. PubMed ID: 22713096 [TBL] [Abstract][Full Text] [Related]
16. Genetic relationship of fluconazole non-susceptible Candida glabrata isolates from nine Korean hospitals. Kim SH; Shin JH; Joo MY; Lee MK; Lee HS; Kim MN; Shin MG; Suh SP; Ryang DW Mycoses; 2011 Sep; 54(5):e659-62. PubMed ID: 21605184 [No Abstract] [Full Text] [Related]
17. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683 [TBL] [Abstract][Full Text] [Related]
18. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata. Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323 [TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis. Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755 [TBL] [Abstract][Full Text] [Related]
20. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]